firstpost_logo

Firstpost

title

About Firstpost

Instagram

Facebook

Twitter

Youtube

social_link

footer_headings

copy_right_year

static_pages

sticky_footer

taboolaFooter

search

President Donald Trump has launched a fresh phase of his trade confrontation, this time aimed at the global pharmaceutical sector. Starting in October, imports of branded and patented medicines into the United States will attract a steep 100 percent tariff. The decision puts India, the largest supplier of medicines to the American market, under immediate strain. While generic drugs are still excluded, Washington has begun an expansive inquiry into pharmaceutical imports, creating concerns that more restrictions may follow. Indian firms, which account for nearly one third of America’s medicine supply, are now expected to move production to US soil, hire workers locally, and face higher costs of operation. The impact has already shaken Asian markets, with pharmaceutical stocks tumbling. The fallout could be serious, Indian drug makers risk losing their edge, and American consumers could pay heavily for essential medicines.

 Trump slaps 100 percent tarrifs on drug imports | Vantage with Palki Sharma

https://media.nw18.com/media-assets/wbx6pq/9344f442-4509-4e28-9bc6-0f22b6d00754/10-2025/2-2025/TrRu7wG7rt-DUPJMiWxmL2609-NEW-TARIFFSSHORTSmp4-wBRjAUA5d1/1080highp-h264.mp4

Trump slaps 100 percent tarrifs on drug imports | Vantage with Palki ...